Effect Domains
Neutral research domains. These labels organize evidence; they are not promises about outcomes.
safety-other
GLP-1-based therapies, multi-agent, Semaglutide, Tirzepatide
pharmacology
Semaglutide, Tirzepatide, GLP-1-based therapies, multi-agent
weight-loss
Dulaglutide, Orforglipron, CagriSema
body-composition
GLP-1-based therapies, multi-agent, Retatrutide, Liraglutide
Stomach and gut
GLP-1-based therapies, multi-agent, Orforglipron, CagriSema
appetite-intake
Retatrutide, Semaglutide, Liraglutide
Specific groups of people
Semaglutide, Tirzepatide, GLP-1-based therapies, multi-agent
glycaemic
Dulaglutide, Retatrutide, CagriSema
Liver and MASH
Multi-agent review synthesis, Cotadutide, Efinopegdutide
Heart and circulation
Semaglutide, Dulaglutide, Retatrutide
renal
Native glucagon physiology, Dulaglutide, Tirzepatide
Brain and mood
GLP-1-based therapies, multi-agent, Exenatide, Semaglutide
Head-to-head comparisons
Tirzepatide, Orforglipron, CagriSema
insulin-beta-cell
Retatrutide, Tirzepatide and semaglutide comparison, Exenatide
Heart rate
Native glucagon physiology, Cotadutide, Retatrutide
energy-expenditure-thermogenesis
Tirzepatide, Semaglutide, Retatrutide
lipids-lipoprotein
Retatrutide, Pemvidutide, Survodutide
Heart failure
Liraglutide, Semaglutide, Tirzepatide
weight-maintenance-regain
GLP-1-based therapies, multi-agent, Semaglutide, Tirzepatide
blood-pressure
CagriSema, Survodutide, Mazdutide
Sleep apnoea
Tirzepatide, GLP-1-based therapies, multi-agent, Liraglutide
Cost and sticking with it
GLP-1-based therapies, multi-agent, Tirzepatide, Semaglutide